{"a":[{"_":"Cue chalks up phase 2 hives win for Xolair challenger","$":{"href":"/biotech/cue-chalks-phase-2-hives-win-xolair-challenger","hreflang":"en"}}]}

Phase 2positiveXolair challengerPositive

AI Analysis

Summary

Cue Biopharma announced that its investigational hives drug achieved the primary endpoint in a Phase 2 trial, advancing the program toward Phase 2b/3 testing as a potential competitor to Xolair.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase 2 study hit primary endpoint

Importance:6/10

Sentiment:

0.80

clinical_trialphase_2hivesimmunologydrug_development

Related Companies

$CUE

Read the original article

Published by FierceBiotech on September 21, 2026 3:52 AM

Read Original